Identification of patients with high-risk lymph node-negative colorectal cancer and potential benefit from adjuvant chemotherapy

Japanese Journal of Clinical Oncology

Volumn 34, Issue 6, 2004, Pages 323-328

  Oñate Ocaña, Luis F ^a   Montesdeoca, Rene ^a   López Graniel, Carlos M ^a   Aiello Crocifoglio, Vincenzo ^a   Mondragón Sánchez, Ricardo ^a   Cortina Borja, Mario ^b   Herrera Goepfert, Roberto ^a   Oros Ovalle, Cuauhtemoc ^a   Gallardo Rincón, Dolores ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant chemotherapy; Colorectal adenocarcinoma; Lymph node negative; Prognostic factors; Recurrent disease

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT IDENTIFICATION; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SURVIVAL RATE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; METHODOLOGY; MIDDLE AGED; NURSING; PATHOLOGY; TIME; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 6044273873     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh054     Document Type: Article

References (23)

1. Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997;40:483-93.
2. Secretaría de Salud, Asociación Mexicana de Patólogos, A.C. Instituto Nacional de Cancerología, Colon. In: Compendio del Registro Histopatológico de Neoplasias Malignas en México. Secretaría de Salud (ed.) Dirección General de Epidemiología. Ciudad de México, Mexico 1997; 93-7.
3. Tovar-Guzman V, Flores-Aldana M, Salmeron-Castro J, Lazcano-Ponce EC. Epidemiologic panorama of colorectal cancer in Mexico, 1980-1993. Dis Colon Rectum 1998;41:225-31.
4. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-96.
5. National Institutes of Health. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 1990; 264:1444-50.
6. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995;122:321-5.
7. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330:1136-42.
8. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995;13:2936-43.
9. American Joint Committee on Cancer. Colon and rectum. In: American Joint Committee on Cancer: Cancer Staging Manual, 5th ed. Philadelphia, PA, USA: Lippincott-Raven Publishers 1997;83-8.
10. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of resected large intestinal carcinomas. Hum Pathol 1996;27:5-8.
11. Kaplan EL, Meier PM. Nonparametric estimation from incomplete observations. J Am Statist Soc 1958;53:457-81.
12. Feinstein AR. Proportional hazards analysis (Cox regression). In: Multivariable Analysis: An introduction, Feinstein AR, editor. New Haven, CO, USA: Yale University Press 1996;370-97.
13. Therneau TM, Grambsch PM. Testing Proportional Hazards. In: Modeling Survival Data: Extending the Cox model, Therneau and Grambsch editors. New York, NY, USA: Springer-Verlag Co. 2000;127-52.
14. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: A multivariate analysis of 572 patients. J Am Coll Surg 1997;185:55-9.
15. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-8.
16. Liefers GJ, Cleton-Jansen AM, van de Velde CJH, Hermans J, van Krieken JHJM, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-8.
17. Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Werner M, et al. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 2002;20:1049-55.
18. Yasuda K, Adachi Y, Shiraishi N, Yamaguchi K, Hirabayashi Y, Kitano S. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 2001;8:300-4.
19. Tschmelitsch J, Klimstra DS, Cohen AM. Lymph node micrometastases do not predict relapse in stage II colon cancer. Ann Surg Oncol 2000;7: 601-8.
20. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001;44:523-33.
21. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001;8:305-10.
22. Meterissian SH, Kontogiannea M, Al-Sowaidi M, Linjawi A, Halwani F, Jamison B, et al. Bcl-2 is a useful prognostic marker in Dukes' B colon cancer. Ann Surg Oncol 2001;8:533-7.
23. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr. Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300.